Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate
| Autor: | Ambrose Aboud, Hwee-Yong Yap, Aman U. Buzdar, Gabriel N. Hortobagyi, George R. Blumenschein |
|---|---|
| Rok vydání: | 1984 |
| Předmět: |
Oncology
medicine.medical_specialty Neutropenia Cyclophosphamide Vomiting medicine.medical_treatment Leucovorin Breast Neoplasms Metastasis Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Doxorubicin Stomatitis Chemotherapy business.industry Alopecia Nausea Combination chemotherapy Bacterial Infections General Medicine medicine.disease Metastatic breast cancer Methotrexate Fluorouracil Female Surgery business medicine.drug |
| Zdroj: | Journal of Surgical Oncology. 26:205-207 |
| ISSN: | 1096-9098 0022-4790 |
| DOI: | 10.1002/jso.2930260315 |
| Popis: | Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue. Of 24 evaluable patients, one achieved a complete remission and 17 had partial responses. The overall objective response rate was 75%. The median survival from initiation of chemotherapy for the responding patients was 18 months. Four patients (17%) with stable disease had a median survival of 25 months. The addition of MTX to FAC chemotherapy did not improve the therapeutic efficacy of this combination; it did, however, increase the overall toxicity, especially the infectious complications when compared to FAC alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text